AR034585A1 - Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos - Google Patents
Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientosInfo
- Publication number
- AR034585A1 AR034585A1 ARP020101168A ARP020101168A AR034585A1 AR 034585 A1 AR034585 A1 AR 034585A1 AR P020101168 A ARP020101168 A AR P020101168A AR P020101168 A ARP020101168 A AR P020101168A AR 034585 A1 AR034585 A1 AR 034585A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- compounds
- heteroarylalkyl
- arylalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Un compuesto de fórmula (1) sus enantiómeros, diastereómeros, sales farmacéuticamente aceptables, profármacos y solvatos de los mismos caracterizado porque: R1 se selecciona del grupo que consiste de hidrógeno, alquilo y cicloalquilo; R2 y R3 son cada uno independientemente seleccionados del grupo que consiste de H, alquilo, arilo, heteroarilo, arilalquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo; o R2 y R3 pueden también ser tomados en conjunto para formar un anillo heterocíclico o carbocíclico; R4 se selecciona del grupo que consiste de alquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilo, aminoalquilo, heterocicloalquilalquilo, CN, C(O)R5, CO2R5 y CONR5R6; R5 y R6 son cada uno independientemente seleccionados del grupo que consiste de H, alquilo, cicloalquilo, hidroxialquilo, alquenilo, alcoxi, tioalcoxi, alcoxialquilo, haloalquilo, arilo, heteroarilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo y heterocicloalquilalquilo, o N-R5R6 juntos forman un heterocicloalquilo; Z se selecciona del grupo que consiste de O, S y NR8; R8 se selecciona del grupo que consiste de H, CN, sulfoamido, OR7, alquilo, cicloalquilo, arilo, arilalquilo, heterociclilo, heteroarilo y heteroarilalquilo; y R7 se selecciona del grupo que consiste de H, alquilo, arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo, Los compuestos de fórmula (1) inducen interrupción mitótica haciéndolos con ello útiles como agentes anticancerígenos. Los compuestos de fórmula (1) son también empleados para el tratamiento de otros padecimientos, los cuales pueden ser tratados induciendo interrupción mitótica. Composición farmacéutica y procedimientos para preparar los compuestos de fórmula (1) y los intermediarios.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27995601P | 2001-03-29 | 2001-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034585A1 true AR034585A1 (es) | 2004-03-03 |
Family
ID=23071059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101168A AR034585A1 (es) | 2001-03-29 | 2002-03-27 | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6809102B2 (es) |
| EP (1) | EP1373221A4 (es) |
| JP (1) | JP2005504725A (es) |
| KR (1) | KR20030086327A (es) |
| CN (1) | CN1507435A (es) |
| AR (1) | AR034585A1 (es) |
| BG (1) | BG108180A (es) |
| BR (1) | BR0208405A (es) |
| CA (1) | CA2442482A1 (es) |
| CZ (1) | CZ20032645A3 (es) |
| EE (1) | EE200300474A (es) |
| HR (1) | HRP20030875A2 (es) |
| HU (1) | HUP0400350A3 (es) |
| IL (1) | IL157441A0 (es) |
| IS (1) | IS6967A (es) |
| MX (1) | MXPA03008634A (es) |
| NO (1) | NO20034300L (es) |
| PE (1) | PE20021013A1 (es) |
| PL (1) | PL373759A1 (es) |
| RU (1) | RU2003130961A (es) |
| SK (1) | SK11062003A3 (es) |
| TW (1) | TWI228416B (es) |
| UY (1) | UY27232A1 (es) |
| WO (1) | WO2002079149A2 (es) |
| YU (1) | YU75803A (es) |
| ZA (2) | ZA200306648B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900214B2 (en) * | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| PT1847534E (pt) * | 2001-12-11 | 2011-08-01 | Kyowa Hakko Kirin Co Ltd | Derivado de tiadiozolina para o tratamento do cancro |
| AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
| KR20050107784A (ko) * | 2003-03-07 | 2005-11-15 | 아스트라제네카 아베 | 신규한 융합 복소환 및 이의 용도 |
| EP1616866B1 (en) | 2003-04-18 | 2011-12-14 | Kyowa Hakko Kirin Co., Ltd. | M-stage kinesin inhibitor |
| WO2004111024A1 (ja) * | 2003-06-10 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | チアジアゾリン誘導体 |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| US20050282838A1 (en) * | 2003-10-16 | 2005-12-22 | Shyamlal Ramchandani | Compounds, compositions, and methods |
| KR20070044458A (ko) * | 2004-07-22 | 2007-04-27 | 아스트라제네카 아베 | 암의 예방 및 치료에 유용한 융합 피리미돈 |
| KR20070046176A (ko) * | 2004-08-18 | 2007-05-02 | 아스트라제네카 아베 | 특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도 |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
| CN101193878A (zh) * | 2005-03-22 | 2008-06-04 | 协和发酵工业株式会社 | 实体肿瘤治疗剂 |
| US20080262049A1 (en) * | 2005-03-22 | 2008-10-23 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic Agent for Hematopoietic Tumor |
| EP1908755A4 (en) * | 2005-06-24 | 2009-06-24 | Kyowa Hakko Kirin Co Ltd | THERAPEUTIC AGENT AGAINST RESTENOSIS |
| DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
| CN110464722B (zh) * | 2019-06-06 | 2023-05-23 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
| PL320263A1 (en) | 1994-11-16 | 1997-09-15 | Synaptic Pharma Corp | Dihydropyrimidines and their application |
| WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| AU727972B2 (en) | 1996-05-16 | 2001-01-04 | H. Lundbeck A/S | Dihydropyrimidines and uses thereof |
| US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| US6080760A (en) | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
| EP1003511A1 (en) | 1997-06-18 | 2000-05-31 | Merck & Co., Inc. | ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS |
| WO1999025345A1 (en) | 1997-11-14 | 1999-05-27 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| WO1999050440A2 (en) | 1998-04-01 | 1999-10-07 | Yale University | Method to identify modulators of survivin - tubulin interaction |
| US6300084B1 (en) | 1998-10-08 | 2001-10-09 | The Regents Of The University Of California | Anti-mitotic agent screening process |
| AUPQ171999A0 (en) | 1999-07-20 | 1999-08-12 | University Of Sydney, The | Neurotropic virus transport |
| DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
| MXPA02004162A (es) | 1999-10-27 | 2003-08-20 | Cytokinetics Inc | Metodo y composiciones que utilizan quinazolinonas. |
| US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
| US6284480B1 (en) | 2000-04-03 | 2001-09-04 | Cytokinetics, Inc. | Antifungal assay |
| US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
-
2002
- 2002-03-22 US US10/104,257 patent/US6809102B2/en not_active Expired - Lifetime
- 2002-03-25 TW TW091105771A patent/TWI228416B/zh not_active IP Right Cessation
- 2002-03-25 PE PE2002000232A patent/PE20021013A1/es not_active Application Discontinuation
- 2002-03-26 CZ CZ20032645A patent/CZ20032645A3/cs unknown
- 2002-03-26 HU HU0400350A patent/HUP0400350A3/hu unknown
- 2002-03-26 MX MXPA03008634A patent/MXPA03008634A/es unknown
- 2002-03-26 BR BR0208405-8A patent/BR0208405A/pt not_active IP Right Cessation
- 2002-03-26 EP EP02728592A patent/EP1373221A4/en not_active Withdrawn
- 2002-03-26 CA CA002442482A patent/CA2442482A1/en not_active Abandoned
- 2002-03-26 SK SK1106-2003A patent/SK11062003A3/sk unknown
- 2002-03-26 IL IL15744102A patent/IL157441A0/xx unknown
- 2002-03-26 EE EEP200300474A patent/EE200300474A/xx unknown
- 2002-03-26 KR KR10-2003-7012604A patent/KR20030086327A/ko not_active Application Discontinuation
- 2002-03-26 YU YU75803A patent/YU75803A/sh unknown
- 2002-03-26 RU RU2003130961/04A patent/RU2003130961A/ru not_active Application Discontinuation
- 2002-03-26 CN CNA028074556A patent/CN1507435A/zh active Pending
- 2002-03-26 JP JP2002577776A patent/JP2005504725A/ja not_active Withdrawn
- 2002-03-26 PL PL02373759A patent/PL373759A1/xx not_active Application Discontinuation
- 2002-03-26 WO PCT/US2002/009497 patent/WO2002079149A2/en active Search and Examination
- 2002-03-27 AR ARP020101168A patent/AR034585A1/es unknown
- 2002-03-27 UY UY27232A patent/UY27232A1/es not_active Application Discontinuation
-
2003
- 2003-08-26 ZA ZA200306648A patent/ZA200306648B/en unknown
- 2003-09-17 BG BG108180A patent/BG108180A/xx unknown
- 2003-09-18 ZA ZA200307320A patent/ZA200307320B/en unknown
- 2003-09-24 IS IS6967A patent/IS6967A/is unknown
- 2003-09-26 NO NO20034300A patent/NO20034300L/no not_active Application Discontinuation
- 2003-10-28 HR HR20030875A patent/HRP20030875A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20034300D0 (no) | 2003-09-26 |
| YU75803A (sh) | 2006-05-25 |
| TWI228416B (en) | 2005-03-01 |
| HRP20030875A2 (en) | 2004-08-31 |
| JP2005504725A (ja) | 2005-02-17 |
| WO2002079149A3 (en) | 2003-02-27 |
| ZA200306648B (en) | 2004-11-26 |
| KR20030086327A (ko) | 2003-11-07 |
| MXPA03008634A (es) | 2003-12-08 |
| NO20034300L (no) | 2003-11-07 |
| US6809102B2 (en) | 2004-10-26 |
| RU2003130961A (ru) | 2005-04-10 |
| SK11062003A3 (sk) | 2004-08-03 |
| WO2002079149A2 (en) | 2002-10-10 |
| PL373759A1 (en) | 2005-09-05 |
| EP1373221A4 (en) | 2004-09-29 |
| BR0208405A (pt) | 2004-03-30 |
| PE20021013A1 (es) | 2002-11-10 |
| CN1507435A (zh) | 2004-06-23 |
| CZ20032645A3 (cs) | 2004-06-16 |
| EE200300474A (et) | 2003-12-15 |
| HUP0400350A3 (en) | 2005-06-28 |
| IL157441A0 (en) | 2004-03-28 |
| BG108180A (en) | 2004-09-30 |
| EP1373221A2 (en) | 2004-01-02 |
| IS6967A (is) | 2003-09-24 |
| UY27232A1 (es) | 2002-11-29 |
| US20030008888A1 (en) | 2003-01-09 |
| ZA200307320B (en) | 2004-12-20 |
| CA2442482A1 (en) | 2002-10-10 |
| HUP0400350A2 (hu) | 2005-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034585A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR036107A1 (es) | Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| AR035777A1 (es) | Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina | |
| EA200600364A1 (ru) | Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| WO2006046031A8 (en) | Pharmaceutical compounds | |
| AR072545A1 (es) | Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| EA200701640A1 (ru) | Новые соединения с терапевтическим эффектом | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
| AR057296A1 (es) | Diarilsulfona sulfonamidas y el uso de las mismas | |
| PE20020735A1 (es) | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b | |
| PE20020657A1 (es) | Derivados de amida de piperidinas 1,4-disustituidas de formula (i) | |
| CO5700763A2 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra | |
| AR056613A1 (es) | Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |